On Thursday, Shares of Mobileye NV (NYSE:MBLY), gained 1.85% to $42.34.
Mobileye N.V. (MBLY), declared that Ofer Maharshak, the Company’s Chief Financial Officer and Senior Vice President, is planned to present at the Deutsche Bank Global Auto Industry Conference in Detroit on Wednesday, January 13, 2016 at 2:05 p.m. EST.
Mobileye N.V., together with its auxiliaries, designs and develops software and related technologies for camera-based advanced driver assistance systems primarily in Israel. It operates through two segments, Original Equipment Manufacturing and After Market.
Shares of Cobalt International Energy, Inc. (NYSE:CIE), inclined 2.47% to $5.40, during its last trading session.
On Monday, December 28, 2015, Nasdaq Composite ended at 5,040.99, down 0.15%, Dow Jones Industrial Average declined 0.14%, to finish the day at 17,528.27, and the S&P 500 closed at 2,056.50, down 0.22%.
The stock of Cobalt International Energy Inc. lost 4.08% to close Monday’s session at USD 5.41. The shares of the company moved in the range of USD 5.34 and USD 5.51. A trading volume of 1.83 million shares was recorded, which was lower than its 150-day daily average volume of 3.71 million shares and was below its 52-week average volume of 3.64 million shares. Over the last five days Cobalt International Energy Inc.’s shares have advanced 1.88% while in the past one month the stock has lost 33.13%. Additionally, over the last three months the stock has declined 21.59% and in the past six months the shares have registered a loss of 44.74%. Moreover, the stock is trading at a price to book ratio of 1.20, which compares to a historical PB ratio near to 1.72. Further, the stock is having a 52-week range of USD 5.14 – USD 11.20.
Cobalt International Energy, Inc., through its auxiliaries, engages in the exploration and production of oil-focused, below-salt exploration prospects. Its project portfolio comprises North Platte, Heidelberg, Shenandoah, and Anchor discovery in the U.S. Gulf of Mexico; Cameia, Lontra, Mavinga, Bicuar, and Orca in the offshore Angola; and Diaman in the offshore Gabon.
Finally, Mylan NV (NASDAQ:MYL), ended its last trade with -1.01% loss, and closed at $54.07.
Mylan N.V., declared the U.S. launch of Linezolid Tablets, 600 mg, which is the generic version of Pfizer’s Zyvox® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated in adults and children for the treatment of certain infections caused by susceptible Gram-positive bacteria.
Linezolid Tablets, 600 mg, had U.S. sales of about $457.8 million for the 12 months ending Sept. 30, 2015, according to IMS Health.
Presently, Mylan has 269 ANDAs pending FDA approval representing $100.8 billion in annual brand sales, according to IMS Health. Fifty of these pending ANDAs are potential first-to-file opportunities, representing $35.6 billion in annual brand sales, for the 12 months ending June 30, 2015, according to IMS Health.
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).